Home Journals Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy

Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy

Credits to the Source Link Daniel
Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy
    • Vilstrup H.
    • Amodio P.
    • Bajaj J.
    • Cordoba J.
    • Ferenci P.
    • Mullen K.D.
    • et al.

    Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.

    Hepatology. 2014; 60: 715-735

    • Balzano T.
    • Forteza J.
    • Borreda I.
    • Molina P.
    • Giner J.
    • Leone P.
    • et al.

    Histological features of cerebellar neuropathology in patients with alcoholic and nonalcoholic steatohepatitis.

    J Neuropathol Exp Neurol. 2018; 77: 837-845

    • Forton D.M.
    • Allsop J.M.
    • Main J.
    • Foster G.R.
    • Thomas H.C.
    • Taylor-Robinson S.D.

    Evidence for a cerebral effect of the hepatitis C virus.

    Lancet. 2001; 358: 38-39

    • Mosher V.A.L.
    • Swain M.G.
    • Pang J.X.Q.
    • Kaplan G.G.
    • Sharkey K.A.
    • MacQueen G.M.
    • et al.

    Magnetic resonance imaging evidence of hippocampal structural changes in patients with primary biliary cholangitis.

    Clin Transl Gastroenterol. 2018; 9: 169

    • Grover V.P.B.
    • Southern L.
    • Dyson J.K.
    • Kim J.U.
    • Crossey M.M.E.
    • Wylezinska-Arridge M.
    • et al.

    Early primary biliary cholangitis is characterised by brain abnormalities on cerebral magnetic resonance imaging.

    Aliment Pharmacol Ther. 2016; 44: 936-945

    • Garcia-Martinez R.
    • Rovira A.
    • Alonso J.
    • Jacas C.
    • Simón-Talero M.
    • Chavarria L.
    • et al.

    Hepatic encephalopathy is associated with posttransplant cognitive function and brain volume.

    Liver Transpl. 2011; 17: 38-46

    • Sotil E.U.
    • Gottstein J.
    • Ayala E.
    • Randolph C.
    • Blei A.T.

    Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation.

    Liver Transpl. 2009; 15: 184-192

    • Hirode G.
    • Vittinghoff E.
    • Wong R.J.

    Increasing burden of hepatic encephalopathy among hospitalized adults: an analysis of the 2010-2014 National Inpatient Sample.

    Dig Dis Sci. 2019; 64: 1448-1457

    • Tapper E.B.
    • Finkelstein D.
    • Mittleman M.A.
    • Piatkowski G.
    • Chang M.
    • Lai M.

    A quality improvement initiative reduces 30-day rate of readmission for patients with cirrhosis.

    Clin Gastroenterol Hepatol. 2016; 14: 753-759

    • Cordoba J.
    • Ventura-Cots M.
    • Simón-Talero M.
    • Amorós À.
    • Pavesi M.
    • Vilstrup H.
    • et al.

    Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF).

    J Hepatol. 2014; 60: 275-281

  • Neurotransmitter dysfunction in hepatic encephalopathy: new approaches and new findings.

    Metab Brain Dis. 2001; 16: 55-65

    • Hadjihambi A.
    • Harrison I.F.
    • Costas-Rodríguez M.
    • Vanhaecke F.
    • Arias N.
    • Gallego-Durán R.
    • et al.

    Impaired brain glymphatic flow in experimental hepatic encephalopathy.

    J Hepatol. 2019; 70: 40-49

    • Bjerring P.N.
    • Gluud L.L.
    • Larsen F.S.

    Cerebral blood flow and metabolism in hepatic encephalopathy-a meta-analysis.

    J Clin Exp Hepatol. 2018; 8: 286-293

    • Görg B.
    • Karababa A.
    • Häussinger D.

    Hepatic encephalopathy and astrocyte senescence.

    J Clin Exp Hepatol. 2018; 8: 294-300

    • Weiss N.
    • Barbier Saint Hilaire P.
    • Colsch B.
    • Isnard F.
    • Attala S.
    • Schaefer A.
    • et al.

    Cerebrospinal fluid metabolomics highlights dysregulation of energy metabolism in overt hepatic encephalopathy.

    J Hepatol. 2016; 65: 1120-1130

    • Dam G.
    • Keiding S.
    • Munk O.L.
    • Ott P.
    • Vilstrup H.
    • Bak L.K.
    • et al.

    Hepatic encephalopathy is associated with decreased cerebral oxygen metabolism and blood flow, not increased ammonia uptake.

    Hepatology. 2013; 57: 258-265

    • Lu K.
    • Zimmermann M.
    • Görg B.
    • Bidmon H.-J.
    • Biermann B.
    • Klöcker N.
    • et al.

    Hepatic encephalopathy is linked to alterations of autophagic flux in astrocytes.

    EBioMedicine. 2019; 48: 539-553

    • Tapper E.B.
    • Henderson J.B.
    • Parikh N.D.
    • Ioannou G.N.
    • Lok A.S.

    Incidence of and risk factors for hepatic encephalopathy in a population-based cohort of Americans with cirrhosis.

    Hepatol Commun. 2019; 3: 1510-1519

    • Saunders J.B.
    • Walters J.R.
    • Davies A.P.
    • Paton A.

    A 20-year prospective study of cirrhosis.

    Br Med J (Clin Res Ed). 1981; 282: 263-266

    • Jepsen P.
    • Ott P.
    • Andersen P.K.
    • Sørensen H.T.
    • Vilstrup H.

    Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study.

    Hepatology. 2010; 51: 1675-1682

    • D’amico G.
    • Morabito A.
    • Pagliaro L.
    • Marubini E.

    Survival and prognostic indicators in compensated and decompensated cirrhosis.

    Dig Dis Sci. 1986; 31: 468-475

    • Nolte W.
    • Wiltfang J.
    • Schindler C.
    • Münke H.
    • Unterberg K.
    • Zumhasch U.
    • et al.

    Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations.

    Hepatology. 1998; 28: 1215-1225

    • Fonio P.
    • Discalzi A.
    • Calandri M.
    • Doriguzzi Breatta A.
    • Bergamasco L.
    • Martini S.
    • et al.

    Incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS) according to its severity and temporal grading classification.

    Radiol Med. 2017; 122: 713-721

    • Lauridsen M.M.
    • Jepsen P.
    • Vilstrup H.

    Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy: a comparative study of 154 patients with liver disease.

    Metab Brain Dis. 2011; 26: 135-139

    • Romero-Gómez M.
    • Córdoba J.
    • Jover R.
    • del Olmo J.A.
    • Ramírez M.
    • Rey R.
    • et al.

    Value of the critical flicker frequency in patients with minimal hepatic encephalopathy.

    Hepatology. 2007; 45: 879-885

    • Allampati S.
    • Duarte-Rojo A.
    • Thacker L.R.
    • Patidar K.R.
    • White M.B.
    • Klair J.S.
    • et al.

    Diagnosis of minimal hepatic encephalopathy using Stroop EncephalApp: a multicenter US-based, norm-based study.

    Am J Gastroenterol. 2016; 111: 78-86

    • Guevara M.
    • Baccaro M.E.
    • Torre A.
    • Gómez-Ansón B.
    • Ríos J.
    • Torres F.
    • et al.

    Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis.

    Am J Gastroenterol. 2009; 104: 1382-1389

    • Jepsen P.
    • Watson H.
    • Andersen P.K.
    • Vilstrup H.

    Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients.

    J Hepatol. 2015; 63: 1133-1138

    • Duarte-Rojo A.
    • Allampati S.
    • Thacker L.R.
    • Flud C.R.
    • Patidar K.R.
    • White M.B.
    • et al.

    Diagnosis of covert hepatic encephalopathy: a multi-center study testing the utility of single versus combined testing.

    Metab Brain Dis. 2018; 34: 289-295

    • Sharma B.C.
    • Sharma P.
    • Agrawal A.
    • Sarin S.K.

    Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.

    Gastroenterology. 2009; 137 (): 885-891

    • Bass N.M.
    • Mullen K.D.
    • Sanyal A.
    • Poordad F.
    • Neff G.
    • Leevy C.B.
    • et al.

    Rifaximin treatment in hepatic encephalopathy.

    N Engl J Med. 2010; 362: 1071-1081

    • Prasad S.
    • Dhiman R.K.
    • Duseja A.
    • Chawla Y.K.
    • Sharma A.
    • Agarwal R.

    Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy.

    Hepatology. 2007; 45: 549-559

    • Younossi Z.M.
    • Tampi R.
    • Priyadarshini M.
    • Nader F.
    • Younossi I.M.
    • Racila A.

    Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States.

    Hepatology. 2019; 69: 564-572

    • Shaheen A.-A.
    • Nguyen H.H.
    • Congly S.E.
    • Kaplan G.G.
    • Swain M.G.

    Nationwide estimates and risk factors of hospital readmission in patients with cirrhosis in the United States.

    Liver Int. 2019; 39: 878-884

    • Roggeri A.
    • Roggeri D.P.
    • Rossi E.
    • Cinconze E.
    • Gasbarrini A.
    • Preti P.M.
    • et al.

    Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs.

    Hepatic Med Evid Res. 2015; 7: 37-42

    • Pascoli M.D.
    • Ceranto E.
    • Nardi P.D.
    • Donato D.
    • Gatta A.
    • Angeli P.
    • et al.

    Hospitalizations due to cirrhosis: clinical aspects in a large cohort of Italian patients and cost analysis report.

    Dig Dis. 2017; 35: 433-438

    • Bajaj J.S.
    • Wade J.B.
    • Gibson D.P.
    • Heuman D.M.
    • Thacker L.R.
    • Sterling R.K.
    • et al.

    The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers.

    Am J Gastroenterol. 2011; 106: 1646-1653

    • Ferenci P.
    • Lockwood A.
    • Mullen K.
    • Tarter R.
    • Weissenborn K.
    • Blei A.T.

    Hepatic encephalopathy–definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

    Hepatology. 2002; 35: 716-721

    • Reuter B.
    • Walter K.
    • Bissonnette J.
    • Leise M.D.
    • Lai J.
    • Tandon P.
    • et al.

    Assessment of the spectrum of hepatic encephalopathy: a multicenter study.

    Liver Transpl. 2018; 24: 587-594

    • Hassanein T.
    • Blei A.T.
    • Perry W.
    • Hilsabeck R.
    • Stange J.
    • Larsen F.S.
    • et al.

    Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy.

    Am J Gastroenterol. 2009; 104: 1392-1400

    • Rockey D.C.
    • Vierling J.M.
    • Mantry P.
    • Ghabril M.
    • Brown R.S.
    • Alexeeva O.
    • et al.

    Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy.

    Hepatology. 2014; 59: 1073-1083

    • Bajaj J.S.
    • Frederick R.T.
    • Bass N.M.
    • Ghabril M.
    • Coyne K.
    • Margolis M.K.
    • et al.

    Overt hepatic encephalopathy: development of a novel clinician reported outcome tool and electronic caregiver diary.

    Metab Brain Dis. 2016; 31: 1081-1093

    • Bajaj J.S.
    • Cordoba J.
    • Mullen K.D.
    • Amodio P.
    • Shawcross D.L.
    • Butterworth R.F.
    • et al.

    Review article: the design of clinical trials in hepatic encephalopathy–an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement.

    Aliment Pharmacol Ther. 2011; 33: 739-747

    • Montagnese S.
    • Balistreri E.
    • Schiff S.
    • De Rui M.
    • Angeli P.
    • Zanus G.
    • et al.

    Covert hepatic encephalopathy: agreement and predictive validity of different indices.

    World J Gastroenterol. 2014; 20: 15756-15762

    • Thomsen K.L.
    • Macnaughtan J.
    • Tritto G.
    • Mookerjee R.P.
    • Jalan R.

    Clinical and pathophysiological characteristics of cirrhotic patients with grade 1 and minimal hepatic encephalopathy.

    PLoS One. 2016; 11: e0146076

    • Bajaj J.S.
    • Etemadian A.
    • Hafeezullah M.
    • Saeian K.

    Testing for minimal hepatic encephalopathy in the United States: an AASLD survey.

    Hepatology. 2007; 45: 833-834

    • Montagnese S.
    • De Rui M.
    • Angeli P.
    • Amodio P.

    Neuropsychiatric performance in patients with cirrhosis: who is “normal”?.

    J Hepatol. 2017; 66: 825-835

    • Conn H.O.
    • Leevy C.M.
    • Vlahcevic Z.R.
    • Rodgers J.B.
    • Maddrey W.C.
    • Seeff L.
    • et al.

    Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial.

    Gastroenterology. 1977; 72: 573-583

    • Sawhney R.
    • Holland-Fischer P.
    • Rosselli M.
    • Mookerjee R.P.
    • Agarwal B.
    • Jalan R.

    Role of ammonia, inflammation, and cerebral oxygenation in brain dysfunction of acute-on-chronic liver failure patients.

    Liver Transpl. 2016; 22: 732-742

    • Verma A.
    • Saraswat V.A.
    • Radha Krishna Y.
    • Nath K.
    • Thomas M.A.
    • Gupta R.K.

    In vivo 1H magnetic resonance spectroscopy-derived metabolite variations between acute-on-chronic liver failure and acute liver failure.

    Liver Int. 2008; 28: 1095-1103

    • Jalan R.
    • Stadlbauer V.
    • Sen S.
    • Cheshire L.
    • Chang Y.-M.
    • Mookerjee R.P.

    Role of predisposition, injury, response and organ failure in the prognosis of patients with acute-on-chronic liver failure: a prospective cohort study.

    Crit Care. 2012; 16: R227

    • Moreau R.
    • Jalan R.
    • Gines P.
    • Pavesi M.
    • Angeli P.
    • Cordoba J.
    • et al.

    Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.

    Gastroenterology. 2013; 144 (): 1426-1437

    • Arroyo V.
    • Moreau R.
    • Jalan R.

    Acute-on-chronic liver failure.

    N Engl J Med. 2020; 382: 2137-2145

    • Shah N.J.
    • Neeb H.
    • Kircheis G.
    • Engels P.
    • Häussinger D.
    • Zilles K.

    Quantitative cerebral water content mapping in hepatic encephalopathy.

    Neuroimage. 2008; 41: 706-717

    • Chavarria L.
    • Alonso J.
    • García-Martínez R.
    • Simón-Talero M.
    • Ventura-Cots M.
    • Ramírez C.
    • et al.

    Brain magnetic resonance spectroscopy in episodic hepatic encephalopathy.

    J Cereb Blood Flow Metab. 2013; 33: 272-277

    • Poveda M.-J.
    • Bernabeu A.
    • Concepción L.
    • Roa E.
    • de Madaria E.
    • Zapater P.
    • et al.

    Brain edema dynamics in patients with overt hepatic encephalopathy A magnetic resonance imaging study.

    Neuroimage. 2010; 52: 481-487

    • Winterdahl M.
    • Abbas Z.
    • Noer O.
    • Thomsen K.L.
    • Gras V.
    • Nahimi A.
    • et al.

    Cerebral water content mapping in cirrhosis patients with and without manifest HE.

    Metab Brain Dis. 2019; 34: 1071-1076

    • Joshi D.
    • O’Grady J.
    • Patel A.
    • Shawcross D.
    • Connor S.
    • Deasy N.
    • et al.

    Cerebral oedema is rare in acute-on-chronic liver failure patients presenting with high-grade hepatic encephalopathy.

    Liver Int. 2014; 34: 362-366

    • Wright G.
    • Vairappan B.
    • Stadlbauer V.
    • Mookerjee R.P.
    • Davies N.A.
    • Jalan R.

    Reduction in hyperammonaemia by ornithine phenylacetate prevents lipopolysaccharide-induced brain edema and coma in cirrhotic rats.

    Liver Int. 2012; 32: 410-419

    • Wright G.
    • Davies N.A.
    • Shawcross D.L.
    • Hodges S.J.
    • Zwingmann C.
    • Brooks H.F.
    • et al.

    Endotoxemia produces coma and brain swelling in bile duct ligated rats.

    Hepatology. 2007; 45: 1517-1526

    • Balasubramaniyan V.
    • Wright G.
    • Sharma V.
    • Davies N a
    • Sharifi Y.
    • Habtesion A.
    • et al.

    Ammonia reduction with ornithine phenylacetate restores brain eNOS activity via the DDAH-ADMA pathway in bile duct-ligated cirrhotic rats.

    Am J Physiol Gastrointest Liver Physiol. 2012; 302: G145-G152

    • O’Leary J.G.
    • Reddy K.R.
    • Garcia-Tsao G.
    • Biggins S.W.
    • Wong F.
    • Fallon M.B.
    • et al.

    NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis.

    Hepatology. 2018; 67: 2367-2374

    • Kril J.J.
    • Butterworth R.F.

    Diencephalic and cerebellar pathology in alcoholic and nonalcoholic patients with end-stage liver disease.

    Hepatology. 1997; 26: 837-841

  • Minimal/covert hepatic encephalopathy – impact of comorbid conditions.

    J Clin Exp Hepatol. 2019; 9: 109-111

    • Kamijo K.
    • Pontifex M.B.
    • Khan N.A.
    • Raine L.B.
    • Scudder M.R.
    • Drollette E.S.
    • et al.

    The negative association of childhood obesity to cognitive control of action monitoring.

    Cereb Cortex. 2014; 24: 654-662

    • Reinert K.R.S.
    • Po’e E.K.
    • Barkin S.L.

    The relationship between executive function and obesity in children and adolescents: a systematic literature review.

    J Obes. 2013; 2013: 820956

    • Weinstein G.
    • Zelber-Sagi S.
    • Preis S.R.
    • Beiser A.S.
    • DeCarli C.
    • Speliotes E.K.
    • et al.

    Association of nonalcoholic fatty liver disease with lower brain volume in healthy middle-aged adults in the Framingham study.

    JAMA Neurol. 2018; 75: 97-104

    • Filipović B.
    • Marković O.
    • Đurić V.
    • Filipović B.

    Cognitive changes and brain volume reduction in patients with nonalcoholic fatty liver disease.

    Can J Gastroenterol Hepatol. 2018; 2018: 9638797

    • VanWagner L.B.
    • Terry J.G.
    • Chow L.S.
    • Alman A.C.
    • Kang H.
    • Ingram K.H.
    • et al.

    Nonalcoholic fatty liver disease and measures of early brain health in middle-aged adults: the CARDIA study.

    Obesity (Silver Spring). 2017; 25: 642-651

    • De Chiara F.
    • Heebøll S.
    • Marrone G.
    • Montoliu C.
    • Hamilton-Dutoit S.
    • Ferrandez A.
    • et al.

    Urea cycle dysregulation in non-alcoholic fatty liver disease.

    J Hepatol. 2018; 69: 905-915

    • Seo S.W.
    • Gottesman R.F.
    • Clark J.M.
    • Hernaez R.
    • Chang Y.
    • Kim C.
    • et al.

    Nonalcoholic fatty liver disease is associated with cognitive function in adults.

    Neurology. 2016; 86: 1136-1142

    • Weinstein G.
    • Davis-Plourde K.
    • Himali J.J.
    • Zelber-Sagi S.
    • Beiser A.S.
    • Seshadri S.

    Non-alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle-aged adults: the Framingham Study.

    Liver Int. 2019; 39: 1713-1721

    • Grover V.P.B.
    • Pavese N.
    • Koh S.-B.
    • Wylezinska M.
    • Saxby B.K.
    • Gerhard A.
    • et al.

    Cerebral microglial activation in patients with hepatitis C: in vivo evidence of neuroinflammation.

    J Viral Hepat. 2012; 19: e89-e96

    • Kalaitzakis E.
    • Olsson R.
    • Henfridsson P.
    • Hugosson I.
    • Bengtsson M.
    • Jalan R.
    • et al.

    Malnutrition and diabetes mellitus are related to hepatic encephalopathy in patients with liver cirrhosis.

    Liver Int. 2007; 27: 1194-1201

    • Jalan R.
    • Elton R.A.
    • Redhead D.N.
    • Finlayson N.D.
    • Hayes P.C.

    Analysis of prognostic variables in the prediction of mortality, shunt failure, variceal rebleeding and encephalopathy following the transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage.

    J Hepatol. 1995; 23: 123-128

    • Bajaj J.S.
    • Thacker L.R.
    • Heuman D.M.
    • Sterling R.K.
    • Stravitz R.T.
    • Sanyal A.J.
    • et al.

    Cognitive performance as a predictor of hepatic encephalopathy in pretransplant patients with cirrhosis receiving psychoactive medications: a prospective study.

    Liver Transpl. 2012; 18: 1179-1187

    • Bajaj J.S.
    • O’Leary J.G.
    • Tandon P.
    • Wong F.
    • Kamath P.S.
    • Biggins S.W.
    • et al.

    Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.

    Aliment Pharmacol Ther. 2019; 49: 1518-1527

    • Tapper E.B.
    • Parikh N.D.
    • Sengupta N.
    • Mellinger J.
    • Ratz D.
    • Lok A.S.-F.
    • et al.

    A risk score to predict the development of hepatic encephalopathy in a population-based cohort of patients with cirrhosis.

    Hepatology. 2018; 68: 1498-1507

    • Grønbæk L.
    • Watson H.
    • Vilstrup H.
    • Jepsen P.

    Benzodiazepines and risk for hepatic encephalopathy in patients with cirrhosis and ascites.

    United Eur Gastroenterol J. 2018; 6: 407-412

    • Görg B.
    • Karababa A.
    • Shafigullina A.
    • Bidmon H.J.
    • Häussinger D.

    Ammonia-induced senescence in cultured rat astrocytes and in human cerebral cortex in hepatic encephalopathy.

    Glia. 2015; 63: 37-50

    • Keiding S.
    • Sørensen M.
    • Bender D.
    • Munk O.L.
    • Ott P.
    • Vilstrup H.

    Brain metabolism of 13N-ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography.

    Hepatology. 2006; 43: 42-50

    • Wright G.
    • Noiret L.
    • Damink S.W.M.O.
    • Jalan R.

    Interorgan ammonia metabolism in liver failure: the basis of current and future therapies.

    Liver Int. 2011; 31: 163-175

  • Identifying the direct effects of ammonia on the brain.

    Metab Brain Dis. 2009; 24: 95-102

    • Dasarathy S.
    • Mookerjee R.P.
    • Rackayova V.
    • Rangroo Thrane V.
    • Vairappan B.
    • Ott P.
    • et al.

    Ammonia toxicity: from head to toe?.

    Metab Brain Dis. 2017; 32: 529-538

    • Davuluri G.
    • Allawy A.
    • Thapaliya S.
    • Rennison J.H.
    • Singh D.
    • Kumar A.
    • et al.

    Hyperammonaemia-induced skeletal muscle mitochondrial dysfunction results in cataplerosis and oxidative stress.

    J Physiol (Lond). 2016; 594: 7341-7360

    • Jalan R.
    • Fernandez J.
    • Wiest R.
    • Schnabl B.
    • Moreau R.
    • Angeli P.
    • et al.

    Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013.

    J Hepatol. 2014; 60: 1310-1324

  • Free radicals in the physiological control of cell function.

    Physiol Rev. 2002; 82: 47-95

    • Görg B.
    • Qvartskhava N.
    • Bidmon H.-J.
    • Palomero-Gallagher N.
    • Kircheis G.
    • Zilles K.
    • et al.

    Oxidative stress markers in the brain of patients with cirrhosis and hepatic encephalopathy.

    Hepatology. 2010; 52: 256-265

    • Bosoi C.R.
    • Yang X.
    • Huynh J.
    • Parent-Robitaille C.
    • Jiang W.
    • Tremblay M.
    • et al.

    Systemic oxidative stress is implicated in the pathogenesis of brain edema in rats with chronic liver failure.

    Free Radic Biol Med. 2012; 52: 1228-1235

    • Shawcross D.L.
    • Davies N.A.
    • Williams R.
    • Jalan R.

    Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis.

    J Hepatol. 2004; 40: 247-254

    • Shawcross D.L.
    • Sharifi Y.
    • Canavan J.B.
    • Yeoman A.D.
    • Abeles R.D.
    • Taylor N.J.
    • et al.

    Infection and systemic inflammation, not ammonia, are associated with grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis.

    J Hepatol. 2011; 54: 640-649

    • Montoliu C.
    • Cauli O.
    • Urios A.
    • ElMlili N.
    • Serra M.A.
    • Giner-Duran R.
    • et al.

    3-Nitro-Tyrosine as a peripheral biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis.

    Am J Gastroenterol. 2011; 106: 1629-1637

    • Bosoi C.R.
    • Tremblay M.
    • Rose C.F.

    Induction of systemic oxidative stress leads to brain oedema in portacaval shunted rats.

    Liver Int. 2014; 34: 1322-1329

    • Tripodi V.
    • Contin M.
    • Fernández M.A.
    • Lemberg A.

    Bile acids content in brain of common duct ligated rats.

    Ann Hepatol. 2012; 11: 930-934

    • McMillin M.
    • Frampton G.
    • Grant S.
    • Khan S.
    • Diocares J.
    • Petrescu A.
    • et al.

    Bile acid-mediated Sphingosine-1-Phosphate receptor 2 signaling promotes neuroinflammation during hepatic encephalopathy in mice.

    Front Cell Neurosci. 2017; 11: 191

    • Rose C.
    • Butterworth R.F.
    • Zayed J.
    • Normandin L.
    • Todd K.
    • Michalak A.
    • et al.

    Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction.

    Gastroenterology. 1999; 117: 640-644

    • Rovira A.
    • Alonso J.
    • Córdoba J.

    MR imaging findings in hepatic encephalopathy.

    AJNR Am J Neuroradiol. 2008; 29: 1612-1621

    • Bossen L.
    • Ginès P.
    • Vilstrup H.
    • Watson H.
    • Jepsen P.

    Serum sodium as a risk factor for hepatic encephalopathy in patients with cirrhosis and ascites.

    J Gastroenterol Hepatol. 2019; 34: 914-920

    • Watson H.
    • Guevara M.
    • Vilstrup H.
    • Ginès P.

    Improvement of hyponatremia in cirrhosis is associated with improved complex information processing.

    J Gastroenterol Hepatol. 2019; 34: 1999-2003

    • Watson H.
    • Jepsen P.
    • Wong F.
    • Ginès P.
    • Córdoba J.
    • Vilstrup H.

    Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development.

    Metab Brain Dis. 2013; 28: 301-305

    • Ahluwalia V.
    • Heuman D.M.
    • Feldman G.
    • Wade J.B.
    • Thacker L.R.
    • Gavis E.
    • et al.

    Correction of hyponatraemia improves cognition, quality of life, and brain oedema in cirrhosis.

    J Hepatol. 2015; 62: 75-82

  • Neurosteroids in hepatic encephalopathy: novel insights and new therapeutic opportunities.

    J Steroid Biochem Mol Biol. 2016; 160: 94-97

    • Dabrowska K.
    • Skowronska K.
    • Popek M.
    • Obara-Michlewska M.
    • Albrecht J.
    • Zielinska M.

    Roles of glutamate and glutamine transport in ammonia neurotoxicity: state of the art and question marks.

    Endocr Metab Immune Disord Drug Targets. 2018; 18: 306-315

    • Bosoi C.R.
    • Zwingmann C.
    • Marin H.
    • Parent-Robitaille C.
    • Huynh J.
    • Tremblay M.
    • et al.

    Increased brain lactate is central to the development of brain edema in rats with chronic liver disease.

    J Hepatol. 2014; 60: 554-560

    • Llansola M.
    • Montoliu C.
    • Agusti A.
    • Hernandez-Rabaza V.
    • Cabrera-Pastor A.
    • Gomez-Gimenez B.
    • et al.

    Interplay between glutamatergic and GABAergic neurotransmission alterations in cognitive and motor impairment in minimal hepatic encephalopathy.

    Neurochem Int. 2015; 88: 15-19

    • Iversen P.
    • Mouridsen K.
    • Hansen M.B.
    • Jensen S.B.
    • Sørensen M.
    • Bak L.K.
    • et al.

    Oxidative metabolism of astrocytes is not reduced in hepatic encephalopathy: a PET study with [(11)C]acetate in humans.

    Front Neurosci. 2014; 8: 353

    • Hadjihambi A.
    • Rose C.F.
    • Jalan R.

    Novel insights into ammonia-mediated neurotoxicity pointing to potential new therapeutic strategies.

    Hepatology. 2014; 60: 1101-1103

    • Aceto P.
    • Perilli V.
    • Lai C.
    • Ciocchetti P.
    • Vitale F.
    • Sollazzi L.

    Postoperative cognitive dysfunction after liver transplantation.

    Gen Hosp Psychiatry. 2015; 37: 109-115

    • Campagna F.
    • Montagnese S.
    • Schiff S.
    • Biancardi A.
    • Mapelli D.
    • Angeli P.
    • et al.

    Cognitive impairment and electroencephalographic alterations before and after liver transplantation: what is reversible?.

    Liver Transpl. 2014; 20: 977-986

    • Atluri D.K.
    • Asgeri M.
    • Mullen K.D.

    Reversibility of hepatic encephalopathy after liver transplantation.

    Metab Brain Dis. 2010; 25: 111-113

    • Amodio P.
    • Biancardi A.
    • Montagnese S.
    • Angeli P.
    • Iannizzi P.
    • Cillo U.
    • et al.

    Neurological complications after orthotopic liver transplantation.

    Dig Liver Dis. 2007; 39: 740-747

    • Guarino M.
    • Benito-Leon J.
    • Decruyenaere J.
    • Schmutzhard E.
    • Weissenborn K.
    • Stracciari A.

    EFNS guidelines on management of neurological problems in liver transplantation.

    Eur J Neurol. 2006; 13: 2-9

    • Bajaj J.S.
    • Schubert C.M.
    • Heuman D.M.
    • Wade J.B.
    • Gibson D.P.
    • Topaz A.
    • et al.

    Persistence of cognitive impairment after resolution of overt hepatic encephalopathy.

    Gastroenterology. 2010; 138: 2332-2340

    • Riggio O.
    • Ridola L.
    • Pasquale C.
    • Nardelli S.
    • Pentassuglio I.
    • Moscucci F.
    • et al.

    Evidence of persistent cognitive impairment after resolution of overt hepatic encephalopathy.

    Clin Gastroenterol Hepatol. 2011; 9: 181-183

    • Rai R.
    • Ahuja C.K.
    • Agrawal S.
    • Kalra N.
    • Duseja A.
    • Khandelwal N.
    • et al.

    Reversal of low-grade cerebral edema after lactulose/rifaximin therapy in patients with cirrhosis and minimal hepatic encephalopathy.

    Clin Trans Gastroenterol. 2015; 6: e111

    • García-Lezana T.
    • Oria M.
    • Romero-Giménez J.
    • Bové J.
    • Vila M.
    • Genescà J.
    • et al.

    Cerebellar neurodegeneration in a new rat model of episodic hepatic encephalopathy.

    J Cereb Blood Flow Metab. 2017; 37: 927-937

  • The human gut microbiome in liver diseases.

    Semin Liver Dis. 2017; 37: 128-140

  • The microbiome-gut-brain axis in health and disease.

    Gastroenterol Clin North Am. 2017; 46: 77-89

    • Peterson J.
    • Garges S.
    • Giovanni M.
    • McInnes P.
    • Wang L.
    • Schloss J.A.
    • et al.

    The NIH Human Microbiome Project.

    Genome Res. 2009; 19: 2317-2323

    • Nava G.M.
    • Stappenbeck T.S.

    Diversity of the autochthonous colonic microbiota.

    Gut Microbes. 2011; 2: 99-104

    • Tranah T.H.
    • Vijay G.K.M.
    • Ryan J.M.
    • Shawcross D.L.

    Systemic inflammation and ammonia in hepatic encephalopathy.

    Metab Brain Dis. 2013; 28: 1-5

    • Chen Y.
    • Yang F.
    • Lu H.
    • Wang B.
    • Chen Y.
    • Lei D.
    • et al.

    Characterization of fecal microbial communities in patients with liver cirrhosis.

    Hepatology. 2011; 54: 562-572

    • Qin N.
    • Yang F.
    • Li A.
    • Prifti E.
    • Chen Y.
    • Shao L.
    • et al.

    Alterations of the human gut microbiome in liver cirrhosis.

    Nature. 2014; 513: 59-64

    • Bajaj J.S.
    • Heuman D.M.
    • Hylemon P.B.
    • Sanyal A.J.
    • White M.B.
    • Monteith P.
    • et al.

    Altered profile of human gut microbiome is associated with cirrhosis and its complications.

    J Hepatol. 2014; 60: 940-947

    • Chen Y.
    • Ji F.
    • Guo J.
    • Shi D.
    • Fang D.
    • Li L.

    Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology.

    Sci Rep. 2016; 6: 34055

    • Bajaj J.S.
    • Betrapally N.S.
    • Hylemon P.B.
    • Heuman D.M.
    • Daita K.
    • White M.B.
    • et al.

    Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy.

    Hepatology. 2015; 62: 1260-1271

    • Santiago A.
    • Pozuelo M.
    • Poca M.
    • Gely C.
    • Nieto J.C.
    • Torras X.
    • et al.

    Alteration of the serum microbiome composition in cirrhotic patients with ascites.

    Sci Rep. 2016; 6: 25001

    • Jensen A.
    • Ladegaard Grønkjær L.
    • Holmstrup P.
    • Vilstrup H.
    • Kilian M.

    Unique subgingival microbiota associated with periodontitis in cirrhosis patients.

    Sci Rep. 2018; 8: 10718

    • Kakiyama G.
    • Pandak W.M.
    • Gillevet P.M.
    • Hylemon P.B.
    • Heuman D.M.
    • Daita K.
    • et al.

    Modulation of the fecal bile acid profile by gut microbiota in cirrhosis.

    J Hepatol. 2013; 58: 949-955

    • Chen Y.
    • Guo J.
    • Qian G.
    • Fang D.
    • Shi D.
    • Guo L.
    • et al.

    Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality.

    J Gastroenterol Hepatol. 2015; 30: 1429-1437

    • Bajaj J.S.
    • Betrapally N.S.
    • Hylemon P.B.
    • Thacker L.R.
    • Daita K.
    • Kang D.J.
    • et al.

    Gut microbiota alterations can predict hospitalizations in cirrhosis independent of diabetes mellitus.

    Sci Rep. 2015; 5: 18559

    • Bajaj J.S.
    • Liu E.J.
    • Kheradman R.
    • Fagan A.
    • Heuman D.M.
    • White M.
    • et al.

    Fungal dysbiosis in cirrhosis.

    Gut. 2017; 67: 1146-1154

    • Amodio P.
    • Bemeur C.
    • Butterworth R.
    • Cordoba J.
    • Kato A.
    • Montagnese S.
    • et al.

    The nutritional management of hepatic encephalopathy in patients with cirrhosis: International society for hepatic encephalopathy and nitrogen metabolism consensus.

    Hepatology. 2013; 58: 325-336

    • Plank L.D.
    • Gane E.J.
    • Peng S.
    • Muthu C.
    • Mathur S.
    • Gillanders L.
    • et al.

    Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial.

    Hepatology. 2008; 48: 557-566

    • Córdoba J.
    • López-Hellín J.
    • Planas M.
    • Sabín P.
    • Sanpedro F.
    • Castro F.
    • et al.

    Normal protein diet for episodic hepatic encephalopathy: results of a randomized study.

    J Hepatol. 2004; 41: 38-43

    • Tandon P.
    • Ney M.
    • Irwin I.
    • Ma M.M.
    • Gramlich L.
    • Bain V.G.
    • et al.

    Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value.

    Liver Transpl. 2012; 18: 1209-1216

    • Andersen H.
    • Borre M.
    • Jakobsen J.
    • Andersen P.H.
    • Vilstrup H.

    Decreased muscle strength in patients with alcoholic liver cirrhosis in relation to nutritional status, alcohol abstinence, liver function, and neuropathy.

    Hepatology. 1998; 27: 1200-1206

    • Montano-Loza A.J.
    • Meza-Junco J.
    • Prado C.M.M.
    • Lieffers J.R.
    • Baracos V.E.
    • Bain V.G.
    • et al.

    Muscle wasting is associated with mortality in patients with cirrhosis.

    Clin Gastroenterol Hepatol. 2012; 10: 166-173

    • Nardelli S.
    • Lattanzi B.
    • Torrisi S.
    • Greco F.
    • Farcomeni A.
    • Gioia S.
    • et al.

    Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement.

    Clin Gastroenterol Hepatol. 2017; 15: 934-936

    • Gioia S.
    • Merli M.
    • Nardelli S.
    • Lattanzi B.
    • Pitocchi F.
    • Ridola L.
    • et al.

    The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS.

    Liver Int. 2019; 39: 871-877

    • Bhanji R.A.
    • Moctezuma-Velazquez C.
    • Duarte-Rojo A.
    • Ebadi M.
    • Ghosh S.
    • Rose C.
    • et al.

    Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis.

    Hepatol Int. 2018; 12: 377-386

    • Hanai T.
    • Shiraki M.
    • Watanabe S.
    • Kochi T.
    • Imai K.
    • Suetsugu A.
    • et al.

    Sarcopenia predicts minimal hepatic encephalopathy in patients with liver cirrhosis.

    Hepatol Res. 2017; 47: 1359-1367

    • Merli M.
    • Giusto M.
    • Lucidi C.
    • Giannelli V.
    • Pentassuglio I.
    • Di Gregorio V.
    • et al.

    Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study.

    Metab Brain Dis. 2013; 28: 281-284

    • Kumar A.
    • Davuluri G.
    • Silva R.N.E.
    • Engelen M.P.K.J.
    • Ten Have G.A.M.
    • Prayson R.
    • et al.

    Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis.

    Hepatology. 2017; 65: 2045-2058

    • Fozouni L.
    • Wang C.W.
    • Lai J.C.

    Sex differences in the association between frailty and sarcopenia in patients with cirrhosis.

    Clin Transl Gastroenterol. 2019; 10: e00102

    • Haugen C.E.
    • McAdams-DeMarco M.
    • Holscher C.M.
    • Ying H.
    • Gurakar A.O.
    • Garonzik-Wang J.
    • et al.

    Multicenter study of age, frailty, and waitlist mortality among liver transplant candidates.

    Ann Surg. 2020; 271: 1132-1136

  • Neuropsychiatric complications of liver transplantation.

    Metab Brain Dis. 2001; 16: 3-11

  • Neurological complications occurring after liver transplantation: role of risk factors, hepatic encephalopathy, and acute (on chronic) brain injury.

    Liver Transpl. 2019; 25: 469-487

    • Lué A.
    • Martinez E.
    • Navarro M.
    • Laredo V.
    • Lorente S.
    • Araiz J.J.
    • et al.

    Donor age predicts calcineurin inhibitor induced neurotoxicity after liver transplantation.

    Transplantation. 2019; 103: e211-e215

    • Hopp A.-E.
    • Dirks M.
    • Petrusch C.
    • Goldbecker A.
    • Tryc A.B.
    • Barg-Hock H.
    • et al.

    Hepatic encephalopathy is reversible in the long term after liver transplantation.

    Liver Transpl. 2019; 25: 1661-1672

    • Grover V.-P.B.
    • Dresner M.-A.
    • Forton D.-M.
    • Counsell S.
    • Larkman D.-J.
    • Patel N.
    • et al.

    Current and future applications of magnetic resonance imaging and spectroscopy of the brain in hepatic encephalopathy.

    World J Gastroenterol. 2006; 12: 2969-2978

    • Baker L.
    • Lanz B.
    • Andreola F.
    • Ampuero J.
    • Wijeyesekera A.
    • Holmes E.
    • et al.

    New technologies – new insights into the pathogenesis of hepatic encephalopathy.

    Metab Brain Dis. 2016; 31: 1259-1267

    • Patel N.
    • White S.
    • Dhanjal N.S.
    • Oatridge A.
    • Taylor-Robinson S.D.

    Changes in brain size in hepatic encephalopathy: a coregistered MRI study.

    Metab Brain Dis. 2004; 19: 431-445

    • Taylor-Robinson S.D.
    • Oatridge A.
    • Hajnal J.V.
    • Burroughs A.K.
    • McIntyre N.
    • deSouza N.M.

    MR imaging of the basal ganglia in chronic liver disease: correlation of T1-weighted and magnetisation transfer contrast measurements with liver dysfunction and neuropsychiatric status.

    Metab Brain Dis. 1995; 10: 175-188

    • Miese F.
    • Kircheis G.
    • Wittsack H.J.
    • Wenserski F.
    • Hemker J.
    • Mödder U.
    • et al.

    1H-MR spectroscopy, magnetization transfer, and diffusion-weighted imaging in alcoholic and nonalcoholic patients with cirrhosis with hepatic encephalopathy.

    AJNR Am J Neuroradiol. 2006; 27: 1019-1026

    • McPhail M.J.W.
    • Leech R.
    • Grover V.P.B.
    • Fitzpatrick J.A.
    • Dhanjal N.S.
    • Crossey M.M.E.
    • et al.

    Modulation of neural activation following treatment of hepatic encephalopathy.

    Neurology. 2013; 80: 1041-1047

    • Haseler L.J.
    • Sibbitt W.L.
    • Mojtahedzadeh H.N.
    • Reddy S.
    • Agarwal V.P.
    • McCarthy D.M.

    Proton MR spectroscopic measurement of neurometabolites in hepatic encephalopathy during oral lactulose therapy.

    AJNR Am J Neuroradiol. 1998; 19: 1681-1686

    • Taylor-Robinson S.D.
    • Sargentoni J.
    • Mallalieu R.J.
    • Bell J.D.
    • Bryant D.J.
    • Coutts G.A.
    • et al.

    Cerebral phosphorus-31 magnetic resonance spectroscopy in patients with chronic hepatic encephalopathy.

    Hepatology. 1994; 20: 1173-1178

    • Bémeur C.
    • Cudalbu C.
    • Dam G.
    • Thrane A.S.
    • Cooper A.J.L.
    • Rose C.F.

    Brain edema: a valid endpoint for measuring hepatic encephalopathy?.

    Metab Brain Dis. 2016; 31: 1249-1258

  • Magnetic resonance imaging and spectroscopy in hepatic encephalopathy.

    J Clin Exp Hepatol. 2015; 5: S69-S74

    • Jackson C.D.
    • Gram M.
    • Halliday E.
    • Olesen S.S.
    • Sandberg T.H.
    • Drewes A.M.
    • et al.

    New spectral thresholds improve the utility of the electroencephalogram for the diagnosis of hepatic encephalopathy.

    Clin Neurophysiol. 2016; 127: 2933-2941

    • Jalan R.
    • Turjanski N.
    • Taylor-Robinson S.D.
    • Koepp M.J.
    • Richardson M.P.
    • Wilson J.A.
    • et al.

    Increased availability of central benzodiazepine receptors in patients with chronic hepatic encephalopathy and alcohol related cirrhosis.

    Gut. 2000; 46: 546-552

    • Kimer N.
    • Krag A.
    • Møller S.
    • Bendtsen F.
    • Gluud L.L.

    Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy.

    Aliment Pharmacol Ther. 2014; 40: 123-132

    • Berding G.
    • Banati R.B.
    • Buchert R.
    • Chierichetti F.
    • Grover V.P.B.
    • Kato A.
    • et al.

    Radiotracer imaging studies in hepatic encephalopathy: ISHEN practice guidelines.

    Liver Int. 2009; 29: 621-628

    • Ventura-Cots M.
    • Carmona I.
    • Moreno C.
    • Ampuero J.
    • Simón-Talero M.
    • Sanpedro F.
    • et al.

    Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients.

    Therap Adv Gastroenterol. 2018; 11 ()

    • Drolz A.
    • Jäger B.
    • Wewalka M.
    • Saxa R.
    • Horvatits T.
    • Roedl K.
    • et al.

    Clinical impact of arterial ammonia levels in ICU patients with different liver diseases.

    Intensive Care Med. 2013; 39: 1227-1237

    • Clemmesen J.O.
    • Larsen F.S.
    • Kondrup J.
    • Hansen B.A.
    • Ott P.

    Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration.

    Hepatology. 1999; 29: 648-653

    • Bhatia V.
    • Singh R.
    • Acharya S.K.

    Predictive value of arterial ammonia for complications and outcome in acute liver failure.

    Gut. 2006; 55: 98-104

    • Bernal W.
    • Hall C.
    • Karvellas C.J.
    • Auzinger G.
    • Sizer E.
    • Wendon J.

    Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure.

    Hepatology. 2007; 46: 1844-1852

    • Ong J.P.
    • Aggarwal A.
    • Krieger D.
    • Easley K.A.
    • Karafa M.T.
    • Lente F.V.
    • et al.

    Correlation between ammonia levels and the severity of hepatic encephalopathy.

    Am J Med. 2003; 114: 188-193

    • Kumar R.
    • Shalimar
    • Sharma H.
    • Prakash S.
    • Panda S.K.
    • Khanal S.
    • et al.

    Persistent hyperammonemia is associated with complications and poor outcomes in patients with acute liver failure.

    Clin Gastroenterol Hepatol. 2012; 10: 925-931

    • Nicolao F.
    • Efrati C.
    • Masini A.
    • Merli M.
    • Attili A.F.
    • Riggio O.

    Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalopathy.

    J Hepatol. 2003; 38: 441-446

    • Patwardhan V.R.
    • Jiang Z.G.
    • Risech-Neiman Y.
    • Piatkowski G.
    • Afdhal N.H.
    • Mukamal K.
    • et al.

    Serum ammonia in associated with transplant-free survival in hospitalized patients with acutely decompensated cirrhosis.

    J Clin Gastroenterol. 2016; 50: 345-350

    • Shalimar
    • Sheikh M.F.
    • Mookerjee R.P.
    • Agarwal B.
    • Acharya S.K.
    • Jalan R.

    Prognostic role of ammonia in patients with cirrhosis.

    Hepatology. 2019; 70: 982-994

    • Vierling J.M.
    • Mokhtarani M.
    • Brown R.S.
    • Mantry P.
    • Rockey D.C.
    • Ghabril M.
    • et al.

    Fasting blood ammonia predicts risk and frequency of hepatic encephalopathy episodes in patients with cirrhosis.

    Clin Gastroenterol Hepatol. 2016; 14: 903-906.e1

    • Zacharias H.D.
    • Zacharias A.P.
    • Gluud L.L.
    • Morgan M.Y.

    Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.

    Cochrane Database Syst Rev. 2019; 6: CD012334

    • Ampuero J.
    • Gil A.
    • Viloria M.D.M.
    • Rico M.C.
    • Millán R.
    • Camacho I.
    • et al.

    Oral glutamine challenge is a marker of altered ammonia metabolism and predicts the risk of hepatic encephalopathy.

    Liver Int. 2019; 40: 921-930

    • Gluud L.L.
    • Vilstrup H.
    • Morgan M.Y.

    Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.

    Cochrane Database Syst Rev. 2016; 4: CD003044

    • Hassanein T.I.
    • Tofteng F.
    • Brown R.S.
    • McGuire B.
    • Lynch P.
    • Mehta R.
    • et al.

    Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis.

    Hepatology. 2007; 46: 1853-1862

    • Bajaj J.S.
    • Bloom P.P.
    • Chung R.T.
    • Hassanein T.I.
    • Padilla-Martinez M.
    • Kayali Z.
    • et al.

    Variability and lability of ammonia levels in healthy volunteers and patients with cirrhosis: implications for trial design and clinical practice.

    Am J Gastroenterol. 2020; 115: 783-785

    • Hashim I.A.
    • Cuthbert J.A.

    Elevated ammonia concentrations: potential for pre-analytical and analytical contributing factors.

    Clin Biochem. 2014; 47: 233-236

    • Rahimi R.S.
    • Safadi R.
    • Thabut D.
    • Bajaj J.S.
    • Bhamidimarri K.R.
    • Pyrsopoulos N.T.
    • et al.

    STOP-HE: a randomized, double-blind, placebo-controlled study of OCR-002 in patients with hepatic encephalopathy.

    Hepatology. 2017; 66: 276A

    • Ditisheim S.
    • Giostra E.
    • Burkhard P.R.
    • Goossens N.
    • Mentha G.
    • Hadengue A.
    • et al.

    A capillary blood ammonia bedside test following glutamine load to improve the diagnosis of hepatic encephalopathy in cirrhosis.

    BMC Gastroenterol. 2011; 11: 134

    • Mani A.R.
    • Montagnese S.
    • Jackson C.D.
    • Jenkins C.W.
    • Head I.M.
    • Stephens R.C.
    • et al.

    Decreased heart rate variability in patients with cirrhosis relates to the presence and degree of hepatic encephalopathy.

    Am J Physiol Gastrointest Liver Physiol. 2009; 296: G330-G338

    • Jansen C.
    • Chatterjee D.A.
    • Thomsen K.L.
    • Al-Kassou B.
    • Sawhney R.
    • Jones H.
    • et al.

    Significant reduction in heart rate variability is a feature of acute decompensation of cirrhosis and predicts 90-day mortality.

    Aliment Pharmacol Ther. 2019; 50: 568-579

    • Campagna F.
    • Montagnese S.
    • Ridola L.
    • Senzolo M.
    • Schiff S.
    • Rui M.D.
    • et al.

    The animal naming test: an easy tool for the assessment of hepatic encephalopathy.

    Hepatology. 2017; 66: 198-208

    • Neumann T.
    • Baum A.K.
    • Baum U.
    • Deike R.
    • Feistner H.
    • Scholz M.
    • et al.

    Assessment of the technical usability and efficacy of a new portable dry-electrode EEG recorder: first results of the HOMEONE study.

    Clin Neurophysiol. 2019; 130: 2076-2087

  • Ammonia-lowering strategies for the treatment of hepatic encephalopathy.

    Clin Pharmacol Ther. 2012; 92: 321-331

    • Bajaj J.S.
    • Gillevet P.M.
    • Patel N.R.
    • Ahluwalia V.
    • Ridlon J.M.
    • Kettenmann B.
    • et al.

    A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy.

    Metab Brain Dis. 2012; 27: 205-215

    • Rahimi R.S.
    • Singal A.G.
    • Cuthbert J.A.
    • Rockey D.C.

    Lactulose vs polyethylene glycol 3350–electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial.

    JAMA Intern Med. 2014; 174: 1727-1733

    • Bajaj J.S.
    • Heuman D.M.
    • Sanyal A.J.
    • Hylemon P.B.
    • Sterling R.K.
    • Stravitz R.T.
    • et al.

    Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.

    PLoS One. 2013; 8: e60042

  • Review article: the antimicrobial effects of rifaximin on the gut microbiota.

    Aliment Pharmacol Ther. 2015; 43: 3-10

    • Kimer N.
    • Pedersen J.S.
    • Tavenier J.
    • Christensen J.E.
    • Busk T.M.
    • Hobolth L.
    • et al.

    Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: a randomized trial.

    J Gastroenterol Hepatol. 2018; 33: 307-314

    • Mas A.
    • Rodés J.
    • Sunyer L.
    • Rodrigo L.
    • Planas R.
    • Vargas V.
    • et al.

    Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.

    J Hepatol. 2003; 38: 51-58

    • Miglio F.
    • Valpiani D.
    • Rossellini S.R.
    • Ferrieri A.

    Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.

    Curr Med Res Opin. 1997; 13: 593-601

    • Paik Y.-H.
    • Lee K.S.
    • Han K.-H.
    • Song K.H.
    • Kim M.H.
    • Moon B.S.
    • et al.

    Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.

    Yonsei Med J. 2005; 46: 399-407

    • Jiang Q.
    • Jiang X.-H.
    • Zheng M.-H.
    • Jiang L.-M.
    • Chen Y.-P.
    • Wang L.

    Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis.

    Eur J Gastroenterol Hepatol. 2008; 20: 1064-1070

    • Eltawil K.M.
    • Laryea M.
    • Peltekian K.
    • Molinari M.

    Rifaximin vs conventional oral therapy for hepatic encephalopathy: a meta-analysis.

    World J Gastroenterol. 2012; 18: 767-777

  • Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.

    Curr Med Res Opin. 1993; 13: 109-118

    • Sharma B.C.
    • Sharma P.
    • Lunia M.K.
    • Srivastava S.
    • Goyal R.
    • Sarin S.K.

    A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.

    Am J Gastroenterol. 2013; 108: 1458-1463

    • Dalal R.
    • McGee R.G.
    • Riordan S.M.
    • Webster A.C.

    Probiotics for people with hepatic encephalopathy.

    Cochrane Database Syst Rev. 2017; 2: CD008716

    • Gluud L.L.
    • Dam G.
    • Les I.
    • Marchesini G.
    • Borre M.
    • Aagaard N.K.
    • et al.

    Branched-chain amino acids for people with hepatic encephalopathy.

    Cochrane Database Syst Rev. 2017; 5: CD001939

    • Bai M.
    • Yang Z.
    • Qi X.
    • Fan D.
    • Han G.

    L-ornithine-L-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.

    J Gastroenterol Hepatol. 2013; 28: 783-792

    • Butterworth R.F.
    • Kircheis G.
    • Hilger N.
    • McPhail M.J.W.

    Efficacy of l-ornithine l-aspartate for the treatment of hepatic encephalopathy and hyperammonemia in cirrhosis: systematic review and meta-analysis of randomized controlled trials.

    J Clin Exp Hepatol. 2018; 8: 301-313

    • Butterworth R.F.
    • McPhail M.J.W.

    L-Ornithine L-Aspartate (LOLA) for hepatic encephalopathy in cirrhosis: results of randomized controlled trials and meta-analyses.

    Drugs. 2019; 79: 31-37

    • Goh E.T.
    • Stokes C.S.
    • Sidhu S.S.
    • Vilstrup H.
    • Gluud L.L.
    • Morgan M.Y.

    L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.

    Cochrane Database Syst Rev. 2018; 5: CD012410

    • Laleman W.
    • Simon-Talero M.
    • Maleux G.
    • Perez M.
    • Ameloot K.
    • Soriano G.
    • et al.

    Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy.

    Hepatology. 2013; 57: 2448-2457

    • Privitera G.
    • Figorilli F.
    • Jalan R.
    • Mehta G.

    Portosystemic shunt embolization and recurrent ascites: a single-center case series.

    Gastroenterology. 2018; 155: 1649-1650

    • Simón-Talero M.
    • García-Martínez R.
    • Torrens M.
    • Augustin S.
    • Gómez S.
    • Pereira G.
    • et al.

    Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study.

    J Hepatol. 2013; 59: 1184-1192

    • Sharma B.C.
    • Singh J.
    • Srivastava S.
    • Sangam A.
    • Mantri A.K.
    • Trehanpati N.
    • et al.

    Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy.

    J Gastroenterol Hepatol. 2017; 32: 1234-1239

    • Bañares R.
    • Nevens F.
    • Larsen F.S.
    • Jalan R.
    • Albillos A.
    • Dollinger M.
    • et al.

    Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial.

    Hepatology. 2013; 57: 1153-1162

  • Enhanced renal ammonia excretion following volume expansion in patients with well compensated cirrhosis of the liver.

    Gut. 2003; 52: 1041-1045

    • Slack A.J.
    • Auzinger G.
    • Willars C.
    • Dew T.
    • Musto R.
    • Corsilli D.
    • et al.

    Ammonia clearance with haemofiltration in adults with liver disease.

    Liver Int. 2014; 34: 42-48

    • Sharma P.
    • Sharma B.C.
    • Agrawal A.
    • Sarin S.K.

    Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose.

    J Gastroenterol Hepatol. 2012; 27: 1329-1335

    • Lunia M.K.
    • Sharma B.C.
    • Sharma P.
    • Sachdeva S.
    • Srivastava S.

    Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial.

    Clin Gastroenterol Hepatol. 2014; 12: 1003-1008.e1

    • Dhiman R.K.
    • Thumburu K.K.
    • Chopra M.
    • Dutta U.
    • Duseja A.
    • Chawla Y.K.

    Comparative effectiveness of different pharmacological interventions for the treatment of minimal hepatic encephalopathy: a systematic review with network meta-analysis.

    Hepatology. 2016; 64: 711A

    • Agrawal A.
    • Sharma B.C.
    • Sharma P.
    • Sarin S.K.

    Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy.

    Am J Gastroenterol. 2012; 107: 1043-1050

    • Mullen K.D.
    • Sanyal A.J.
    • Bass N.M.
    • Poordad F.F.
    • Sheikh M.Y.
    • Frederick R.T.
    • et al.

    Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy.

    Clin Gastroenterol Hepatol. 2014; 12: 1390-1397.e2

    • Dhiman R.K.
    • Rana B.
    • Agrawal S.
    • Garg A.
    • Chopra M.
    • Thumburu K.K.
    • et al.

    Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial.

    Gastroenterology. 2014; 147: 1327-1337.e3

    • Caraceni P.
    • Riggio O.
    • Angeli P.
    • Alessandria C.
    • Neri S.
    • Foschi F.G.
    • et al.

    Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.

    Lancet. 2018; 391: 2417-2429

    • Jalan R.
    • Wright G.
    • Davies N.A.
    • Hodges S.J.

    L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy.

    Med Hypotheses. 2007; 69: 1064-1069

    • Kristiansen R.G.
    • Rose C.F.
    • Fuskevåg O.-M.
    • Mæhre H.
    • Revhaug A.
    • Jalan R.
    • et al.

    L-Ornithine phenylacetate reduces ammonia in pigs with acute liver failure through phenylacetylglycine formation: a novel ammonia-lowering pathway.

    Am J Physiol Gastrointest Liver Physiol. 2014; 307: G1024-G1031

    • Ytrebø L.M.
    • Kristiansen R.G.
    • Maehre H.
    • Fuskevåg O.M.
    • Kalstad T.
    • Revhaug A.
    • et al.

    L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure.

    Hepatology. 2009; 50: 165-174

    • Oria M.
    • Romero-Giménez J.
    • Arranz J.A.
    • Riudor E.
    • Raguer N.
    • Córdoba J.

    Ornithine phenylacetate prevents disturbances of motor-evoked potentials induced by intestinal blood in rats with portacaval anastomosis.

    J Hepatol. 2012; 56: 109-114

    • Safadi R.
    • Rahimi R.S.
    • DiLiberti C.E.
    • Wang L.
    • Pyrsopoulos N.T.
    • Potthoff A.
    • et al.

    OCR-002 (ornithine phenylacetate) is a potent ammonia scavenger as demonstrated in phase 2b STOP-HE study.

    Hepatology. 2017; 66: 126A

    • Weiss N.
    • Tripon S.
    • Lodey M.
    • Guiller E.
    • Junot H.
    • Monneret D.
    • et al.

    Treating hepatic encephalopathy in cirrhotic patients admitted to ICU with sodium phenylbutyrate: a preliminary study.

    Fundam Clin Pharmacol. 2018; 32: 209-215

    • Kao D.
    • Roach B.
    • Park H.
    • Hotte N.
    • Madsen K.
    • Bain V.
    • et al.

    Fecal microbiota transplantation in the management of hepatic encephalopathy.

    Hepatology. 2016; 63: 339-340

    • Bajaj J.S.
    • Kassam Z.
    • Fagan A.
    • Gavis E.A.
    • Liu E.
    • Cox I.J.
    • et al.

    Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial.

    Hepatology. 2017; 66: 1727-1738

    • Mullish B.H.
    • McDonald J.A.K.
    • Thursz M.R.
    • Marchesi J.R.

    Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial.

    Hepatology. 2017; 66: 1354-1355

    • Agostoni V.
    • Lee S.H.
    • Forster V.
    • Kabbaj M.
    • Bosoi C.R.
    • Tremblay M.
    • et al.

    Liposome-supported peritoneal dialysis for the treatment of hyperammonemia-associated encephalopathy.

    Adv Funct Mater. 2016; 26: 8382-8389

    • Kurtz C.B.
    • Millet Y.A.
    • Puurunen M.K.
    • Perreault M.
    • Charbonneau M.R.
    • Isabella V.M.
    • et al.

    An engineered E. coli nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans.

    Sci Transl Med. 2019; 11: eaau7975

  • Synlogic Discontinues Development of SYNB1020 to Treat Hyperammonemia. Synlogic n.d. Available at: https://investor.synlogictx.com/news-releases/news-release-details/synlogic-discontinues-development-synb1020-treat-hyperammonemia. [Accessed October 23, 2019].

    • Bosoi C.R.
    • Parent-Robitaille C.
    • Anderson K.
    • Tremblay M.
    • Rose C.F.

    AST-120 (spherical carbon adsorbent) lowers ammonia levels and attenuates brain edema in bile-duct ligated rats.

    Hepatology. 2011; 53: 1995-2002

    • Johansson M.
    • Agusti A.
    • Llansola M.
    • Montoliu C.
    • Strömberg J.
    • Malinina E.
    • et al.

    GR3027 antagonizes GABAA receptor-potentiating neurosteroids and restores spatial learning and motor coordination in rats with chronic hyperammonemia and hepatic encephalopathy.

    Am J Physiol Gastrointest Liver Physiol. 2015; 309: G400-G409

    • Johansson M.
    • Strömberg J.
    • Ragagnin G.
    • Doverskog M.
    • Bäckström T.

    GABAA receptor modulating steroid antagonists (GAMSA) are functional in vivo.

    J Steroid Biochem Mol Biol. 2016; 160: 98-105

    • Agusti A.
    • Llansola M.
    • Hernández-Rabaza V.
    • Cabrera-Pastor A.
    • Montoliu C.
    • Felipo V.

    Modulation of GABAA receptors by neurosteroids. A new concept to improve cognitive and motor alterations in hepatic encephalopathy.

    J Steroid Biochem Mol Biol. 2016; 160: 88-93

    • Desjardins P.
    • Rao K.V.
    • Michalak A.
    • Rose C.
    • Butterworth R.F.

    Effect of portacaval anastomosis on glutamine synthetase protein and gene expression in brain, liver and skeletal muscle.

    Metab Brain Dis. 1999; 14: 273-280

    • Jover-Cobos M.
    • Noiret L.
    • Lee K.
    • Sharma V.
    • Habtesion A.
    • Romero-Gomez M.
    • et al.

    Ornithine phenylacetate targets alterations in the expression and activity of glutamine synthase and glutaminase to reduce ammonia levels in bile duct ligated rats.

    J Hepatol. 2014; 60: 545-553

    • Chatauret N.
    • Desjardins P.
    • Zwingmann C.
    • Rose C.
    • Rao K.V.R.
    • Butterworth R.F.

    Direct molecular and spectroscopic evidence for increased ammonia removal capacity of skeletal muscle in acute liver failure.

    J Hepatol. 2006; 44: 1083-1088

    • Qvartskhava N.
    • Lang P.A.
    • Görg B.
    • Pozdeev V.I.
    • Ortiz M.P.
    • Lang K.S.
    • et al.

    Hyperammonemia in gene-targeted mice lacking functional hepatic glutamine synthetase.

    Proc Natl Acad Sci U S A. 2015; 112: 5521-5526

    • Hakvoort T.B.M.
    • He Y.
    • Kulik W.
    • Vermeulen J.L.M.
    • Duijst S.
    • Ruijter J.M.
    • et al.

    Pivotal role of glutamine synthetase in ammonia detoxification.

    Hepatology. 2017; 65: 281-293

    • Torres-Vega M.A.
    • Vargas-Jerónimo R.Y.
    • Montiel-Martínez A.G.
    • Muñoz-Fuentes R.M.
    • Zamorano-Carrillo A.
    • Pastor A.R.
    • et al.

    Delivery of glutamine synthetase gene by baculovirus vectors: a proof of concept for the treatment of acute hyperammonemia.

    Gene Ther. 2015; 22: 58-64

    • Song G.
    • Kerbert A.
    • Jones H.
    • Davies N.
    • Andreola F.
    • Nicolson T.
    • et al.

    Recombinant glutamine synthetase: a novel strategy for the treatment of hyperammonemia and consequent hepatic encephalopathy in rodent model of cirrhosis and urea cycle enzyme deficiency.

    J Hepatol. 2019; 70: e93-e94

    • Romero-Gómez M.
    • Montagnese S.
    • Jalan R.

    Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure.

    J Hepatol. 2015; 62: 437-447

    • Lauridsen M.M.
    • Mikkelsen S.
    • Svensson T.
    • Holm J.
    • Klüver C.
    • Gram J.
    • et al.

    The continuous reaction time test for minimal hepatic encephalopathy validated by a randomized controlled multi-modal intervention-A pilot study.

    PLoS One. 2017; 12: e0185412

    • Bajaj J.S.
    • Hafeezullah M.
    • Franco J.
    • Varma R.R.
    • Hoffmann R.G.
    • Knox J.F.
    • et al.

    Inhibitory control test for the diagnosis of minimal hepatic encephalopathy.

    Gastroenterology. 2008; 135: 1591-1600.e1

    • Montagnese S.
    • Schiff S.
    • Turco M.
    • Bonato C.A.
    • Ridola L.
    • Gatta A.
    • et al.

    Simple tools for complex syndromes: a three-level difficulty test for hepatic encephalopathy.

    Dig Liver Dis. 2012; 44: 957-960

    • Marchetti P.
    • D’Avanzo C.
    • Orsato R.
    • Montagnese S.
    • Schiff S.
    • Kaplan P.W.
    • et al.

    Electroencephalography in patients with cirrhosis.

    Gastroenterology. 2011; 141 (): 1680-1689

    • Kircheis G.
    • Hilger N.
    • Häussinger D.

    Value of critical flicker frequency and psychometric hepatic encephalopathy score in diagnosis of low-grade hepatic encephalopathy.

    Gastroenterology. 2014; 146: 961-969.e11

  • Brain metabolism in patients with hepatic encephalopathy studied by PET and MR.

    Arch Biochem Biophys. 2013; 536: 131-142

    • Gabriel MM
    • Kircheis G
    • Hardtke S
    • Markwardt D
    • Buggisch P
    • Mix H
    • et al.

    Risk of recurrent hepatic encephalopathy in patients with liver cirrhosis: a German registry study.

    Eur J Gastroenterol Hepatol. 2020; https://doi.org/10.1097/MEG.0000000000001822

    • Grover VPB
    • Crossey MME
    • Fitzpatrick JA
    • Saxby BK
    • Shaw R
    • Waldman AD
    • et al.

    Quantitative magnetic resonance imaging in patients with cirrhosis: a cross-sectional study.

    Metab Brain Dis. 2016; 31: 1315-1325

    • Poo JL
    • Rosas-Romero R
    • Rodríguez F
    • Silencio JL
    • Muñoz R
    • Bourges H.
    • et al.

    Serum zinc concentrations in two cohorts of 153 healthy subjects and 100 cirrhotic patients from Mexico City.

    Dig Dis. 1995; 13: 136-142

    • Takuma Y
    • Nouso K
    • Makino Y
    • Hayashi M
    • Takahashi H.

    Clinical trial: oral zinc in hepatic encephalopathy.

    Aliment Pharmacol Ther. 2010; 32: 1080-1090

  • Source Link

    Related Articles

    Leave a Comment

    This website uses cookies to improve your experience. We will assume you are ok with this, but you can opt-out if you wish. Accept Read More

    %d bloggers like this: